Acadia Pharmaceuticals ACAD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.64M-98.7% | $273.57M+281% | $71.78M+169% | $26.67M+40.4% | $18.99M-86.8% | ||
| $271K+34.2% | $202K-11.0% | $227K+6.6% | $213K-7.0% | $229K+1.3% | ||
| $14.7M+11.1% | $13.24M+0.4% | $13.18M-8.1% | $14.34M+26.0% | $11.38M+8.9% | ||
| -$94K— | —— | —— | —— | $0— | ||
| $13.89M+148% | $5.61M-32.8% | $8.35M+374% | $1.76M-74.8% | $7M+1,222% | ||
| -$78K-102% | $4.89M— | $0-100% | $4.1M-60.8% | $10.45M+136% | ||
| $1.34M+112% | -$10.84M-757% | $1.65M-17.6% | $2M+5.2% | $1.9M+166% | ||
| $23.56M+134% | -$68.39M-346% | $27.78M+29.4% | $21.47M+18,605% | -$116K-100% | ||
| $32K-98.3% | $1.84M+163% | $700K-2.9% | $721K+23.2% | $585K-96.5% | ||
| -$6.5M-224% | $5.25M+136% | -$14.66M-271% | $8.59M+350% | $1.91M-30.2% | ||
| $5.07M— | —— | $8.12M— | —— | -$2.98M— | ||
| $2.72M0.0% | $2.72M0.0% | $2.72M0.0% | $2.72M0.0% | $2.72M-45.4% | ||
| -$13.74M-530% | $3.19M-72.0% | $11.4M+171% | $4.21M+109% | $2.02M— | ||
| $33.98M— | —— | $74.29M+16.2% | $63.96M+215% | $20.32M-49.7% | ||
| $5.21M+30.1% | $4.01M+932% | $388K+30.6% | $297K— | $0-100% | ||
| $15.01M-90.5% | $157.61M-22.9% | $204.55M+17.3% | $174.39M+11.8% | $156.01M+14.9% | ||
| $86.5M-18.2% | $105.75M-15.8% | $125.59M-4.4% | $131.39M+0.5% | $130.8M+16.9% | ||
| $0— | —— | —— | —— | $98.84M— | ||
| $66.28M+219% | -$55.87M+29.6% | -$79.35M-83.3% | -$43.29M+65.1% | -$124.05M— | ||
| $4.23M-81.3% | $22.67M+141% | $9.42M-40.9% | $15.96M+768% | $1.84M-6.7% | ||
| $4.23M-81.3% | $22.67M+141% | $9.42M-40.9% | $15.96M+768% | $1.84M-6.7% | ||
| $25K+257% | $7K— | $0-100% | $24K+580% | -$5K+91.7% | ||
| $104.52M+228% | -$81.93M— | —— | —— | -$101.89M-162% | ||
| —— | $6.29M0.0% | $6.29M0.0% | $6.29M0.0% | $6.29M+28.9% | ||
| $453K-32.4% | $670K-39.2% | $1.1M-28.3% | $1.54M-27.4% | $2.12M-24.9% | ||
| $2.72M0.0% | $2.72M0.0% | $2.72M0.0% | $2.72M0.0% | $2.72M-45.4% | ||
| $271K+34.2% | $202K-11.0% | $227K+6.6% | $213K-7.0% | $229K+1.3% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$13.74M-530% | $3.19M-72.0% | $11.4M+171% | $4.21M+109% | $2.02M— | ||
| -$2.16M+1.5% | -$2.2M+0.7% | -$2.21M-4.2% | -$2.12M+0.7% | -$2.14M+10.1% | ||
| -$2.18M+25.2% | -$2.92M-34.0% | -$2.18M-21.9% | -$1.79M-584% | $369K— | ||
| $32K-96.2% | $850K+21.4% | $700K-2.9% | $721K+23.2% | $585K— | ||
| $5.07M— | —— | $8.12M— | —— | -$2.98M— | ||
| $0— | —— | —— | —— | $98.84M— | ||
| $86.5M-18.2% | $105.75M-15.8% | $125.59M-4.4% | $131.39M+0.5% | $130.8M+16.9% | ||
| $879K+147% | $356K— | —— | $3.28M+332% | $759K+49.4% | ||
| $25K+257% | $7K— | $0-100% | $24K+580% | -$5K+91.7% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $2.2M— | —— | —— | —— | $0— | ||
| $118K-38.9% | $193K— | —— | $214K+128% | $94K+422% | ||
| —— | $6.29M0.0% | $6.29M0.0% | $6.29M0.0% | $6.29M+28.9% | ||
| $28.77M— | —— | $73.9M+16.1% | $63.66M+213% | $20.32M-49.1% | ||
| $28.77M— | —— | $73.9M+16.1% | $63.66M+213% | $20.32M-49.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Acadia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.